Macomics Announces Appointment Of Simon Dew As New Chief Business Officer

( MENAFN - GlobeNewsWire - Nasdaq) EDINBURGH, United Kingdom and CAMBRIDGE, United Kingdom, June 10, 2024 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery has announced the appointment of Simon Dew in the newly created position of Chief Business Officer (CBO). He will be instrumental in advancing Macomics' mission to develop first-in-class medicines targeting macrophage-driven diseases of high unmet medical need, in oncology and chronic inflammatory diseases. With an extensive background in pharmaceutical business development, corporate strategy, Simon will play a pivotal role in maximizing the potential of Macomics' proprietary macrophage ENIGMACTM drug discovery platform through strategic partnerships and collaborations.

Simon brings over 25 years of experience in the pharmaceutical industry, having held senior leadership roles in Pharma and Biotech. He is currently on the Business Development Board of Sunstone Capital, a Danish Venture Capital Company and, most recently served as CBO at ReNeuron Group. His career also includes significant roles at Gyroscope Therapeutics, Astellas Pharmaceuticals, IQVIA, Parexel, Phytopharm plc, and GSK/SB, where he demonstrated exceptional expertise in business development, corporate strategy, and operational leadership.

He has a BSc in Pharmacy and has completed the INSEAD Managing Partnerships and Strategic Alliances and M&A Executive Program. Dr Stephen Myatt, CEO of Macomics said, “I am delighted to welcome Sim.